Rituxan® (rituximab) – Expanded orphan indication
September 27, 2019 - The FDA announced the approval of Genentech’s Rituxan (rituximab), in combination with glucocorticoids, for the treatment of adult and pediatric patients 2 years of age and older with Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA).
Top